Search our site
Search our site

Dr Said Khelwatty

Postdoctoral Fellow

About

I began my higher education at Kingston University in 2005 with an undergraduate degree in Biomedical Sciences. Upon graduating in 2008, I studied undertook a MSc degree in Biomedical Sciences, specialising in Haematology. Subsequently, I started my PhD in Cancer biology and therapeutics in (2009-2012) at Kingston University. 

In 2013, I began my tenure as a Postdoctoral Fellow and have worked on several research projects since. Currently, I am working on a translational cancer research project, which focuses on finding predictive biomarkers for targeted therapy of colorectal cancer patients and is externally funded by BRIGHT charity. I also undertake teaching and training responsibilities for a range of undergraduate and postgraduate students with a focus on cancer related subjects and research techniques.

Areas of specialism

  • Cancer Biology
  • Cancer Diagnostics
  • Cancer Therapeutics
  • Tumour Histopathology
  • Tumour Biomarkers
  • Monoclonal antibodies and small molecule tyrosine kinase inhibitors

Qualifications

  • PhD Cancer Biology and Therapeutics, 2012
  • MSc Biomedical Sciences (Haematology), 2009
  • BSc (Hons) Biomedical Sciences, 2008

Professional membership

Fellow of Institute of Biomedical Science (FIBMS)

Member of American Association for Cancer Research (AACR)

Member of British Association for Cancer Research (BACR)

Research

I have an extensive research background with particular expertise in translational cancer research. I draw strong technical and analytical expertise in biological and clinical significance of growth factor receptor family with tyrosine kinase activity and cancer stem cells in human malignancies, in particular colorectal cancer.

Currently my research interests are in the following areas:

1. Biological and clinical significance and targeting of growth factor receptors with tyrosine kinase activities in colorectal cancer.

2. Predictive biomarkers for response to therapy in colorectal cancer.

3. Development of monoclonal antibody (mAb) products for use in colorectal cancer diagnosis and therapy

Publications

Number of items: 5.

Article

Khelwatty, Said, Essapen, Sharadah, Bagwan, Izhar, Green, Margaret, Seddon, Alan and Modjtahedi, Helmout (2016) The impact of co-expression of wild-type EGFR and its ligands determined by immunohistochemistry for response to treatment with cetuximab in patients with metastatic colorectal cancer. Oncotarget, 8(5), pp. 7666-7677. ISSN (online) 1949-2553

Khelwatty, Said A., Essapen, Sharadah, Seddon, Alan M., Fan, Zhen and Modjtahedi, Helmout (2015) Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers. British Journal of Cancer, 113(7), pp. 1010-1019. ISSN (print) 0007-0920

Khelwatty, Said Abdullah, Essapen, Sharadah, Bagwan, Izhar, Green, Margaret, Seddon, Alan and Modjtahedi, Helmout (2014) Co-expression of HER family members in patients with Dukes' C and D colon cancer and their impacts on patient prognosis and survival. PloS one, 9(3), e91139. ISSN (print) 1932-6203

Conference or Workshop Item

Khelwatty, Said Abdullah, Essapen, Sharadah, Seddon, Alan M., Fan, Zhen and Modjtahedi, Helmout (2013) Acquired resistance to anti-EGFR mAb ICR62 or afatinib is accompanied by upregulation of the EGFR in colorectal cancer. In: 104th Annual Meeting of the American Association for Cancer Research; 6-10 Apr 2013, Washington, U.S.A..

Thesis

Khelwatty, Said Abdullah (2012) The biological and clinical significance of HER family members and cancer stem cells in colorectal cancer and response to therapeutic interventions. (PhD thesis), Kingston University.

This list was generated on Fri Nov 17 04:48:08 2017 GMT.
>

Looking for academic staff in the Faculty of Health, Social Care and Education? Visit the Faculty website

Site menu